X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adolescent (1) 1
adult (1) 1
aged (1) 1
aged, 80 and over (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibody (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
arthritis (1) 1
cancer therapies (1) 1
diagnosis (1) 1
drug administration schedule (1) 1
drug dosages (1) 1
efficacy (1) 1
expansion (1) 1
female (1) 1
giant cell tumors - drug therapy (1) 1
giant cell tumors - immunology (1) 1
giant cell tumors - metabolism (1) 1
giant cell tumors - pathology (1) 1
hematology, oncology and palliative medicine (1) 1
humans (1) 1
imatinib mesylate (1) 1
index medicus (1) 1
infusions, intravenous (1) 1
lupus (1) 1
macrophage colony stimulating factor (1) 1
macrophages (1) 1
male (1) 1
middle aged (1) 1
monoclonal antibodies (1) 1
oncology (1) 1
periorbital edema secondary (1) 1
pigmented villonodular synovitis (1) 1
prescription drugs (1) 1
receptor (1) 1
receptor, macrophage colony-stimulating factor - antagonists & inhibitors (1) 1
receptor, macrophage colony-stimulating factor - immunology (1) 1
receptor, macrophage colony-stimulating factor - metabolism (1) 1
signal transduction - drug effects (1) 1
soft tissue neoplasms - drug therapy (1) 1
soft tissue neoplasms - immunology (1) 1
soft tissue neoplasms - metabolism (1) 1
soft tissue neoplasms - pathology (1) 1
synovitis, pigmented villonodular - drug therapy (1) 1
synovitis, pigmented villonodular - immunology (1) 1
synovitis, pigmented villonodular - metabolism (1) 1
synovitis, pigmented villonodular - pathology (1) 1
therapy (1) 1
time factors (1) 1
treatment outcome (1) 1
tumors (1) 1
young adult (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 949 - 956
Summary Background Diffuse-type tenosynovial giant cell tumour (dt-GCT) of the soft tissue (alternatively known as pigmented villonodular synovitis), an orphan... 
Hematology, Oncology and Palliative Medicine | PIGMENTED VILLONODULAR SYNOVITIS | DIAGNOSIS | THERAPY | EFFICACY | ONCOLOGY | PERIORBITAL EDEMA SECONDARY | MACROPHAGES | RECEPTOR | ANTIBODY | ARTHRITIS | IMATINIB MESYLATE | Receptor, Macrophage Colony-Stimulating Factor - antagonists & inhibitors | Receptor, Macrophage Colony-Stimulating Factor - immunology | Giant Cell Tumors - immunology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Giant Cell Tumors - pathology | Soft Tissue Neoplasms - drug therapy | Male | Antineoplastic Agents - administration & dosage | Giant Cell Tumors - metabolism | Receptor, Macrophage Colony-Stimulating Factor - metabolism | Synovitis, Pigmented Villonodular - drug therapy | Synovitis, Pigmented Villonodular - pathology | Soft Tissue Neoplasms - immunology | Young Adult | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Drug Administration Schedule | Soft Tissue Neoplasms - metabolism | Synovitis, Pigmented Villonodular - metabolism | Treatment Outcome | Synovitis, Pigmented Villonodular - immunology | Giant Cell Tumors - drug therapy | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Infusions, Intravenous | Monoclonal antibodies | Macrophage colony stimulating factor | Tumors
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.